Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.53 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.48 |
| ▸ | SLC34A1 | Q06495 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200565 | 0.86 | LMNA (0.48) | MEN1KMT2ANR1I2LMNASMN1; SMN2 | |
| SCHEMBL2201159 | 0.83 | PDE4B (0.62) | PDE4DPDE4BP2RY12SLC34A1MEN1 | |
| SCHEMBL30900068 | 0.80 | PDE4B (0.71) | PDE4DPDE4BP2RY12MEN1KMT2A | |
| SCHEMBL5904534 | 0.80 | PDE4D (0.70) | PDE4DPDE4BP2RY12SLC34A1NPSR1 | |
| SCHEMBL2201222 | 0.79 | PDE4D (0.67) | PDE4DPDE4BP2RY12SLC34A1MEN1 | |
| SCHEMBL2201286 | 0.79 | PDE4D (0.67) | PDE4DPDE4BP2RY12NPSR1NPC1 | |
| SCHEMBL2201663 | 0.75 | TACR1 (0.42) | KMT2ANR1I2 | |
| SCHEMBL2199926 | 0.74 | PDE4D (0.57) | PDE4DPDE4BP2RY12SLC34A1NPC1 | |
| SCHEMBL2199963 | 0.73 | PDE4D (0.62) | PDE4DPDE4BP2RY12SLC34A1NPC1 | |
| SCHEMBL13506435 | 0.72 | PDE4B (0.48) | PDE4DPDE4BSLC34A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | PDE4D 814/4885PDE4B 607/4885P2RY12 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.